Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Pfizer Inc. | GBT601 | Sickle Cell Disease | Phase 2/3 | Data Released | oral | Hematology |
| Pfizer Inc. | Nurtec ODT (rimegepant) | Chronic rhinosinusitis (CRS) with or without nasal polyps | Phase 2/3 | Trial Completed | Oral | Respiratory |
| Pfizer Inc. | PF-07304814 | Intravenous Protease Inhibitor for COVID-19 | Phase 2/3 | Intravenous | COVID-19 | |
| Pfizer Inc. | Oral Zavegepant | Migraine | Phase 2/3 | Trial Completed | Oral | Neurology |
| Pfizer Inc. | GBT601 (GBT021601-012) | Sickle cell disease (SCD) | Phase 2/3 | Trial Completed | oral | Hematology |
| Pfizer Inc. | Verdiperstat - (HEALEY ALS) | Amyotrophic lateral sclerosis (ALS) | Phase 2/3 | Trial Discontinued | Oral | Neurology |
| Pfizer Inc. | Oral Protease Inhibitor | COVID-19 | Phase 2/3 | Oral | COVID-19 | |
| Pfizer Inc. | Paxalisib (GDC-0084), VAL-083, Troriluzole, and VT1021 - (GBM AGILE) | Glioblastoma (GBM) | Phase 2/3 | Trial Completed | Oral | Oncology |
